机构:[1]Institute of Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, China.四川大学华西医院[2]Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.四川大学华西医院[3]Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.四川大学华西医院[4]Key Laboratory of Medicinal and Edible Plants Resources Development of Sichuan Education Department, School of Pharmacy, Chengdu University, Chengdu, Sichuan, China.[5]Department of Ultrasound, the Affiliated Hospital of Southwest Jiaotong University, the Third People's Hospital of Chengdu City, Chengdu, Sichuan, China.[6]Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.四川大学华西医院[7]Yingshan Hospital, West China Hospital, Sichuan University, Chengdu, Sichuan, China.四川大学华西医院[8]CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, Beijing, China.[9]Department of Colorectal Surgery and Oncology, Center for Medical Research and Innovation in Digestive System Tumors, Ministry of Education, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. wzhuo@zju.edu.cn.[10]Department of Cell Biology, Center for Medical Research and Innovation in Digestive System Tumors, Ministry of Education, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
This work was supported by (1) the
National Natural Science Foundation of China (No. 82404672 to Z.X.;
No. 82172634 to H.S.; No. 82104212 to P.D.); (2) the National Key
Research and Development Program of China (2022YFA1207300 to
J.J.); (3) Key Programof the Science and Technology Bureau of Sichuan
(No. 2021YFSY0007 to H.S.; No. 2024YFFK0352 to D.Z.); (4) 1.3.5
project for disciplines of excellence, West China Hospital, Sichuan University (No. ZYGD23028 to H.S.). (5) the China Postdoctoral Science
Foundation (No. 2023M742486 to Z.X.); (6) the Postdoctoral Fellowship
Program of China Postdoctoral Science Foundation (No.
GZC20231826 to Z.X.).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类|1 区综合性期刊
小类|1 区综合性期刊
最新[2025]版:
大类|1 区综合性期刊
小类|1 区综合性期刊
第一作者:
第一作者机构:[1]Institute of Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, China.[2]Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.[3]Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
共同第一作者:
通讯作者:
通讯机构:[9]Department of Colorectal Surgery and Oncology, Center for Medical Research and Innovation in Digestive System Tumors, Ministry of Education, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. wzhuo@zju.edu.cn.[10]Department of Cell Biology, Center for Medical Research and Innovation in Digestive System Tumors, Ministry of Education, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
推荐引用方式(GB/T 7714):
Xu Zihan,He Xiujing,Gui Yu,et al.Intrapleural pressure-controlled piezo-catalytic nanozyme for the inhibition of malignant pleural effusion[J].Nature Communications.2025,16(1):3194.doi:10.1038/s41467-025-58354-9.
APA:
Xu Zihan,He Xiujing,Gui Yu,Tang Lingkai,Zhao Yuxin...&Shi Hubing.(2025).Intrapleural pressure-controlled piezo-catalytic nanozyme for the inhibition of malignant pleural effusion.Nature Communications,16,(1)
MLA:
Xu Zihan,et al."Intrapleural pressure-controlled piezo-catalytic nanozyme for the inhibition of malignant pleural effusion".Nature Communications 16..1(2025):3194